Ruti Aga's Six-Year Ban: A Glucocorticoid, a Forged Prescription and a Clinic That Never Existed

A half marathon in China, in March. Ruti Aga won it. What reached the Athletics Integrity Unit (AIU) afterwards was a prescription for a knee treatment: a clinic's letterhead, a doctor's name, a date. Three separate verification routes returned the same answer. The clinic had never existed at that address. The person who wrote the prescription was a family member, not a registered physician. And the clinic stated in writing that no “old prescription pad from a former workplace” had ever left its possession. On Thursday the AIU issued its statement: a six-year ban. Two years for the presence of a prohibited substance, four years for tampering with documents.

The knee file was thin; the silence around it was not. Years of writing about injuries have left me with one habit — read the paper first, the statement second. In this case the paper rewrote the story on its own.

Context: an athlete whose value sits in her name, not her legs

Aga is 32. In Ethiopian women's marathoning that is the far end of the peak, not the summit. Her record carries the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. The source report gives no personal best; public records list 2:18:34 for second at Berlin 2026 and 2:20:40 for the Tokyo win. Both figures sit outside the source, so treat them as pending verification. What the source does establish is narrower: no time, no splits, no field description for the Chinese half marathon — only the win. Reading form off that win is like reading bowling pace off a scoreboard.

The economics of that Chinese race matter. For East African marathoners, Asia's label road races are the income tier between Majors: decent appearance fees, a low-risk course, a field that can be won. That same tier is now the AIU's highest-yield testing ground. The race that pays an appearance fee also collects a sample. The fee economy and the testing economy are colliding on the same start line.

Core: two years plus four, and a chemical fact in the middle

Start with the correction the media report got wrong, because it determines the direction of the whole case. Methylprednisolone was described as a “prohibited steroid” and as something WADA classes as performance enhancing. That is imprecise. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (S1). Under the current List, S9 substances are prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out-of-competition is entirely legal. A violation arises only when residues appear in an in-competition sample.

This was never a case about “steroid use”. It was a case about route of administration and distance from the competition date. That is precisely where a legitimate defence existed: timing, route, medical necessity, all provable on paper.

Now the arithmetic. Six years: two for the presence violation, four for tampering. The Code's structure tells the story. Two years is the standard outcome for a Specified Substance without proven intent; anything shorter requires the athlete to establish No Significant Fault. Four years is the standard tampering sanction. The panel found presence proven and closed the door on mitigation, then placed the tampering fully on the athlete.

The ban runs from 10 September. That is procedure, not leniency: provisional suspension time is credited, so the athlete gains nothing in real terms. The statement does not specify the year of the March race or the year the ban began, and I treat those gaps as gaps rather than filling them with inference.

What the statement does make clear matters more. The four-year component came not from a document but from an interview — from statements given under questioning. Language and translation in AIU interviews with Ethiopian athletes have been a recurring point of friction, and this case will reopen it. The room for defence here is narrow, though, because the document placed on the table was broken on its face.

Three verification failures in one prescription

First, the clinic's existence: it never occupied that address. Second, the author's credentials: a family member with no registration. Third, the “old pad” argument: the clinic disowned it directly. That is not a filing error. It is the signature of an athlete competing without a credentialed team physician.

This is where a 2026 lesson returns. In Chicago a midfielder went over on his ankle; the club called it a lateral roll and cleared him in nine days. I sat with the physio and re-watched the tape — the foot was planted and externally rotated. That is a syndesmotic sprain, not a roll. He lasted 22 minutes and then missed five weeks and eleven matches. Since that day I ask for the mechanism before the diagnosis: which joint, loaded in which direction, at what minute, on what surface. Here the mechanism is coherent — a knee injury, treated, in a marathoner's body. Intra-articular methylprednisolone for knee synovitis is standard practice in distance runners.

That plausibility is exactly what makes the case bitter. If the treatment really happened, real records would have defended it; a forged prescription is evidence that concealment was chosen over defence. The paper said the treatment was complete. The knee said nothing.

One structural point belongs here. A properly managed athlete has two routes: hold or apply for a TUE, or observe the route-specific washout period. Neither appears to have happened; a fabricated document happened instead. That does not prove dishonesty. It proves the absence of a structure that could tell the athlete what the legal path looked like. The distinction is large, and it decides who should carry the sanction.

This is not a distant case for Indian athletics

Indian distance running shows the same architecture. A runner's career rests on three documents: a Railways or Services job, TOPS or Khelo India funding, and the calendar of the National Games or a qualifying window. None of the three rewards declaring pain. Writing “knee hurts” into the file makes an athlete unavailable in front of a selection committee. The result is a familiar habit: local injections, undocumented treatment, the calendar placed above the body. Our TUE culture exists on paper, not in practice — ask any state camp how the application is filed and the answer is usually silence.

An old habit applies. Through the 2026 season with the Chicago Fire I kept a spiral ledger on 27 first-team players: every treatment, every tight hamstring, every injection, logged with a time and a clinician's initials. Nobody asked for it at season's end, because the club's injury reports were being phoned in from memory by people who had already left the building. The root is the same as it was in that ledger: paper. Injury news travels fast; injury truth travels with paperwork.

Contrarian: the six years punish the covering, not the substance

Here is what most readers of this story will miss. Methylprednisolone has no proven performance benefit across 42 kilometres. A glucocorticoid reduces inflammation and masks pain — it is a tool for hiding injury, not for going faster. So the bulk of a six-year sanction is not attached to an advantageous abuse. The panel punished the method of concealment, not the substance.

The tempting next step is to call the sanction disproportionate. I do not buy that quickly. Document forgery is the most dangerous offence inside any system, because it disables verification itself: once a fake prescription circulates, the next genuine injury becomes suspect too. The other side of the coin is just as true. Under a sanction of this size, the next athlete goes further underground. When cleaning up costs six years, people stop cleaning up and start hiding pain. The case also shows the enforcement frontier moving from testing to document verification — and the network without paperwork will hit that frontier first.

A pattern deserves recording, not alleging: in recent East African road-racing cases, the initial substance violation is often followed by a second layer of documentary clean-up. Aga's case is not an outlier; it belongs to a recognisable family. The converse is equally true. Because the family is recognisable, more cases are in the pipeline — the same informal medical networks serve many athletes in the same training cluster.

What to watch

Aga's return age would be roughly 38. Ethiopian women's marathon depth means even a 2:18 performer is not automatically selectable; a 38-year-old with a doping record has no realistic route back into a national team. The 2026 Tokyo title and the three Major runner-up finishes stay on the record, since the statement says nothing about annulling earlier results and the violation is anchored to the March race. Commercially, the name is now a liability in a sport where distance-running sponsorship is already thin.

Three things to watch. The CAS appeal window, typically around 21 days from the reasoned decision — the appeal looks weak against documents. Whether the March result and its prize money are formally voided, since standard AIU practice strips the competition result but the statement does not say so. And whether the family member faces action at national level, because document forgery sits outside the AIU's jurisdiction, and that is where this case is left unfinished.

The question I keep is not about the sanction. It is this: if the knee treatment genuinely happened, why did the athlete not hold the real prescription — and why did nobody among her agent, coach and management tell her what the honest paper trail for an honest injury looks like?